Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Empagliflozin

Our opinion on this compoundEstablished, active research

65/100

Landmark SGLT2 inhibitor with definitive outcomes data; class maturity limits novelty but cardiorenal mechanisms remain open

Look, empagliflozin has one of the most consequential outcomes trial records in modern cardiometabolic pharmacology. The EMPA-REG OUTCOME readout in 2015 was genuinely surprising: a 38 percent relative risk reduction in cardiovascular death from a glucose-lowering drug, in a population nobody expected to respond that dramatically. That single trial rewrote prescribing standards globally and forced the field to reconsider what SGLT2 inhibition was actually doing. Thats a decade ago now, and the class has matured considerably since.

What keeps empagliflozin interesting as a research object is the mechanism uncertainty. The glycemic piece is straightforward: inhibit SGLT2 in the S1/S2 segments of the proximal tubule, produce insulin-independent urinary glucose excretion of roughly 60 to 90 grams per day, sidestep the beta cell entirely. Clean and well-characterized. But the cardiovascular and renal protective effects are still being dissected. Is it osmotic diuresis reducing cardiac preload? Direct AMPK activation in cardiomyocytes? Tubuloglomerular feedback blunting intraglomerular hypertension? The answer is probably all three, and their relative contributions aren’t resolved. For mechanistic bench work, that ambiguity is actually the interesting part.

The EMPEROR-Preserved result (2021) deserves more attention than it typically gets outside cardiology. HFpEF had been a pharmacological dead end for decades; nearly every agent that worked in reduced-ejection heart failure failed when applied to the preserved population. Empagliflozin was one of the first to show a meaningful composite endpoint reduction there. We think thats the most scientifically fertile signal in the entire empagliflozin dataset, precisely because the mechanism driving it in that population is still genuinely unclear.

What we dont love: novelty is running low. The gliflozin class entered its second decade and empagliflozin has been on formularies since 2014. Dapagliflozin, with DAPA-HF and DAPA-CKD behind it, is a real competitor on outcomes breadth; the two compounds are roughly equivalent tools for most research questions about SGLT2 biology. The 2500-fold SGLT2/SGLT1 selectivity ratio is a solid structural property, but it doesn’t open new biology the way a first-in-class mechanism does. For most bench programs, the question of whether SGLT2 inhibition does X has already been answered in humans.

The evidence base is essentially as strong as it gets: four major outcomes trials, roughly 25,000 patients across them, regulatory approval spanning T2DM, HFrEF, HFpEF, and CKD. For a research program focused on cardiorenal protection mechanisms, SGLT2/GLP-1 combination biology, or the specific puzzle of HFpEF pharmacology, empagliflozin earns its place as a serious and well-validated tool. For a program hunting at the frontier of metabolic pharmacology, you’re looking at newer molecules.

Novelty

35

Mechanism promise

62

In-category differentiation

65

Evidence quality

88

Translational signal

88

Research bench value

58

Rationale Empagliflozin scores well on evidence and translational signal given multiple landmark RCTs across four approved indications, but takes a real novelty penalty because the gliflozin class is now over a decade old and dapagliflozin offers genuine competition on outcomes breadth. The unresolved hemodynamic/direct cardiac/renal protective mechanisms and the HFpEF signal justify elevated mechanism and bench value scores above a simple approved-drug dismissal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sodium-glucose co-transporter 2 (SGLT2) inhibitor of the C-aryl glucoside structural class

A highly selective SGLT2 inhibitor developed by Boehringer Ingelheim as an oral antihyperglycemic agent, distinguished from other gliflozins by the highest SGLT2-to-SGLT1 selectivity ratio in the class, landmark cardiovascular and renal outcome trial data, and regulatory approval across type 2 diabetes, heart failure with reduced and preserved ejection fraction, and chronic kidney disease.

Abstract

Empagliflozin (BI 10773, marketed as Jardiance) is a potent, orally bioavailable, selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) protein expressed in the S1 and S2 segments of the renal proximal tubule, where it mediates approximately 90 percent of filtered glucose reabsorption. The compound is a C-aryl glucoside bearing a chlorophenyl core linked to a tetrahydrofuranyloxy-substituted benzyl moiety, and it exhibits the highest selectivity for SGLT2 over the intestinal isoform SGLT1 among the marketed gliflozins, with a selectivity ratio exceeding 2500-fold in heterologous expression systems. By inhibiting SGLT2, empagliflozin produces insulin-independent urinary glucose excretion of approximately 60 to 90 grams per day at therapeutic doses, resulting in reductions in fasting and postprandial plasma glucose, glycated hemoglobin (HbA1c), body weight, and systolic blood pressure without increasing hypoglycemia risk when used as monotherapy. Empagliflozin was developed by Boehringer Ingelheim in collaboration with Eli Lilly and Company, received initial regulatory approval in 2014 for the treatment of type 2 diabetes mellitus, and has since undergone one of the most consequential clinical development programs in modern cardiometabolic medicine. The EMPA-REG OUTCOME trial (2015), enrolling 7020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 35 percent reduction in hospitalization for heart failure, results that fundamentally altered the treatment paradigm for type 2 diabetes and prompted regulatory label expansions for cardiovascular risk reduction. The EMPEROR-Reduced trial (2020) demonstrated a 25 percent reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction regardless of diabetes status, while the EMPEROR-Preserved trial (2021) extended this benefit to patients with heart failure and preserved ejection fraction, a population for which few prior therapies had demonstrated efficacy. The EMPA-KIDNEY trial (2022) demonstrated a 28 percent reduction in the composite of kidney disease progression or cardiovascular death in 6609 patients with chronic kidney disease across a broad range of eGFR values. Pharmacokinetics are characterized by rapid oral absorption with peak plasma concentrations at approximately 1.5 hours, steady-state plasma protein binding of 80 to 86 percent, a terminal elimination half-life of approximately 12.4 hours supporting once-daily dosing, and metabolism predominantly through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 without clinically meaningful cytochrome P450 involvement. The compound has minimal drug-drug interaction potential and does not require dose adjustment for hepatic impairment or mild-to-moderate renal impairment, although efficacy on glycemic endpoints diminishes at lower eGFR values where the filtered glucose load is reduced. The principal adverse events are genital mycotic infections (occurring in approximately 5 to 10 percent of female patients and 1 to 5 percent of male patients), urinary tract infections, volume depletion (particularly in elderly patients and those on concomitant diuretics), and rare but serious events including euglycemic diabetic ketoacidosis and necrotizing fasciitis of the perineum (Fournier gangrene). This monograph reviews the chemistry, synthesis, and structural pharmacology of empagliflozin; the SGLT2 inhibitory mechanism in molecular and physiological detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology across metabolic, cardiovascular, and renal models; the landmark clinical evidence base spanning diabetes, heart failure, and chronic kidney disease; sourcing and quality verification; reconstitution and handling for research applications; stack-interaction considerations; adverse-event signal and safety profile; and a comparative assessment of five alternative SGLT2 inhibitors against empagliflozin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1560Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Lisuride

Our opinion on this compoundEstablished, active research

58/100

Old ergoline with a genuinely interesting biased 5-HT2A agonism story worth serious bench attention

Look, lisuride is a compound that deserves more attention than it typically gets, and simultaneously not a frontier compound by any honest measure. Synthesized in Prague in 1960 and developed through Schering AG as a Parkinson’s and hyperprolactinemia treatment, it carries decades of clinical use across European and Asian markets. The dopaminergic pharmacology, D2/D3 agonism with sub-nanomolar Ki values, is exhaustively characterized. That’s the context we’re working in.

What actually makes it worth a second look right now is the 5-HT2A story. Lisuride is a G protein-biased partial agonist at 5-HT2A, and it does this without producing hallucinogenic activity. The hallucinogenic effects of classical ergolines like LSD are generally attributed to beta-arrestin recruitment at 5-HT2A; the neuroplasticity-driving effects track more closely to G protein signaling. Lisuride sits right in that pocket. Research into non-hallucinogenic psychoplastogens has put this compound back on serious investigators’ radar, and the antidepressant angle has genuine preclinical traction going back to the Bhattacharyya group and related biased agonism literature. Thats an interesting contemporary research program for a 65-year-old compound.

The 5-HT2B antagonism matters separately. Ergoline agonists like pergolide and cabergoline carry cardiac valvulopathy risk from 5-HT2B agonism. Lisuride antagonizes that receptor, which is why it doesnt carry the same fibrotic profile, and why pergolide was pulled from most markets while lisuride stayed. Real pharmacological differentiation within the ergoline class, not marketing copy.

The evidence base is substantial for the approved indications: multiple decades of trial data in Parkinson’s disease across oral, continuous subcutaneous infusion, and transdermal formulations, replicated across independent groups. Hyperprolactinemia and migraine evidence is similarly mature. The antidepressant and psychoplastogen angles remain early-stage, with preclinical support but thin clinical replication. That’s the honest picture, and it holds the score down from going higher.

For bench utility, lisuride is a legitimate probe compound if you’re working on biased agonism at 5-HT2A. Pharmaceutical-grade supply is real, PK/PD is characterized across multiple routes, and the absence of hallucinogenicity is actually pharmacologically useful as a separation tool relative to other 5-HT2A ligands. We think there’s a genuine research program here for groups studying non-hallucinogenic plasticity compounds or ergoline SAR. The score reflects a well-characterized, differentiated compound with one genuinely fresh angle: not a frontier compound, but not a boring one either.

Novelty

42

Mechanism promise

65

In-category differentiation

55

Evidence quality

63

Translational signal

65

Research bench value

60

Rationale Lisuride’s core dopaminergic pharmacology is mature and clinically displaced by non-ergolines, but its G protein-biased 5-HT2A partial agonism without hallucinogenicity is a legitimately contemporary research angle. The 5-HT2B antagonism that separates it from the valvulopathy-risk ergolines adds real differentiation within its class, and the psychoplastogen and antidepressant lines of inquiry carry genuine preclinical traction even if clinical replication is thin.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Semisynthetic 8-alpha-ergoline dopamine D2/D3 receptor agonist with multimodal serotonergic, adrenergic, and histaminergic activity

A semisynthetic ergot alkaloid dopamine agonist distinguished from other ergolines by 5-HT2B receptor antagonism (conferring absence of cardiac valvulopathy risk), G protein-biased 5-HT2A partial agonism without hallucinogenic activity, and broad translational applications spanning Parkinson’s disease, hyperprolactinemia, migraine prophylaxis, and emerging antidepressant research.

Abstract

Lisuride (1,1-diethyl-3-[(8-alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea) is a semisynthetic 8-alpha-ergoline derivative first synthesized by Zikan and Semonsky at the Research Institute for Pharmacy and Biochemistry in Prague in 1960 as an antimigraine agent analogous to methysergide. It was subsequently developed by Schering AG (Berlin) as a dopamine D2/D3 receptor agonist for the treatment of Parkinson’s disease, hyperprolactinemia, and migraine prophylaxis, and has been marketed in multiple European, Asian, and Latin American jurisdictions under the brand names Dopergin, Cuvalit, Lysenyl, Revanil, and others. Lisuride is the most potent of the classical ergoline dopamine agonists by receptor binding affinity, with sub-nanomolar Ki values at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, and low-nanomolar affinity across a broad panel of monoamine targets including dopamine D1, D4, and D5 receptors, serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, alpha-1 and alpha-2 adrenergic receptors, and the histamine H1 receptor. This broad receptor engagement, sometimes characterized as “dirty drug” pharmacology, produces a clinically diverse profile that distinguishes lisuride from both the older ergoline bromocriptine and the newer non-ergoline dopamine agonists ropinirole and pramipexole.

Two pharmacological features of lisuride have attracted particular research interest in the 2020s. First, lisuride is a silent antagonist at the serotonin 5-HT2B receptor, in contrast to the ergoline dopamine agonists pergolide and cabergoline, which are 5-HT2B agonists. Because 5-HT2B receptor agonism on cardiac valvular interstitial cells is the established molecular mechanism of the fibrotic cardiac valvulopathy that led to the withdrawal of pergolide and the black-box labeling of cabergoline, the 5-HT2B antagonist profile of lisuride is associated with the absence of cardiac valvulopathy adverse drug reaction reports in pharmacovigilance databases, supporting the concept that 5-HT2B agonism (not ergoline structure per se) is the critical determinant of fibrotic risk [1]. Second, lisuride is a G protein-biased partial agonist at the serotonin 5-HT2A receptor: it activates 5-HT2A-mediated Gq/11 signaling without recruiting beta-arrestin 2, and in consequence does not produce the head-twitch response in rodents or hallucinogenic activity in humans that characterizes the structurally related lysergic acid diethylamide (LSD) and other beta-arrestin-biased 5-HT2A agonists [2, 3]. This biased signaling profile has positioned lisuride as a key pharmacological tool for dissecting the signaling pathways responsible for psychedelic versus therapeutic 5-HT2A receptor effects, and recent preclinical evidence demonstrates that lisuride exerts antidepressant-like and psychoplastogenic effects in mice through G protein-dependent mechanisms without hallucinogenic activity [3].

Pharmacokinetics of oral lisuride are characterized by complete gastrointestinal absorption, high first-pass hepatic metabolism reducing absolute oral bioavailability to 10 to 20 percent, peak plasma concentrations at 60 to 80 minutes, a short elimination half-life of approximately 2 hours, and plasma protein binding of 60 to 70 percent [4]. More than 15 metabolites have been identified. The short half-life motivated the development of continuous subcutaneous infusion protocols for advanced Parkinson’s disease with motor fluctuations (lisuride was the first dopamine agonist used for chronic subcutaneous pump delivery) and transdermal patch formulations intended to provide sustained plasma concentrations and continuous dopaminergic stimulation [5, 6]. Clinical evidence in Parkinson’s disease demonstrates that continuous subcutaneous lisuride infusion significantly reduces off-time and dyskinesia compared to oral levodopa, with sustained benefit over four years in prospective randomized trials [7]. Oral lisuride at doses of 0.6 to 5 mg daily has demonstrated comparable antiparkinsonian efficacy to bromocriptine in adjunctive therapy, though firm conclusions on oral efficacy are limited by the absence of large randomized controlled trials [8, 9]. The compound is well tolerated at clinical doses; the principal adverse events are nausea, dizziness, orthostatic hypotension, and psychiatric effects (hallucinations, confusion) at higher doses, consistent with the dopamine agonist class. The absence of cardiac valvulopathy signal distinguishes the safety profile from pergolide and cabergoline. This monograph reviews the chemistry, synthesis, and receptor pharmacology of lisuride; the comprehensive pharmacokinetic record across oral, subcutaneous, and transdermal routes; the clinical evidence base across Parkinson’s disease, hyperprolactinemia, migraine, and emerging antidepressant indications; sourcing, reconstitution, and stack-interaction considerations; adverse-event signal and safety; and a comparative assessment of five dopamine agonist alternatives against lisuride on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1590Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Tretinoin

Our opinion on this compoundResearch workhorse

59/100

The canonical differentiation therapy and retinoid reference standard, indispensable as a bench tool but exhaustively mapped as a research target

Look, tretinoin is genuinely one of the most important compounds in the modern pharmacopoeia. The 1988 Huang report out of Shanghai Second Medical University changed oncology permanently, turning APL from something that killed patients in weeks to one of the most curable blood cancers we have. Thats not rhetoric. And the Kligman-era dermatology work established four decades of consistent human evidence across photoaging, acne, and collagen biology that almost nothing in this library can match on sheer replication volume. So why does it score 59?

Because this library is about frontier research value, and tretinoin’s frontier has largely been mapped. The mechanism is genuinely sophisticated: ligand-dependent RAR/RXR heterodimer activation, corepressor-coactivator switching via NCoR and SMRT displacement, histone acetyltransferase recruitment, and transcriptional regulation of over 500 target genes. Thats real biology. But its also not new biology. The genomic pharmacology of all-trans-retinoic acid has been interrogated continuously since the early 1980s and the mechanistic picture is essentially complete. Novelty is the compound’s weakest axis under this rubric, and we weight that heavily.

Where tretinoin earns its keep for a research program is bench utility. If you’re studying retinoid biology, RAR subtype selectivity, or running differentiation assays, you need ATRA as your reference standard. The HL-60 and NB4 cell line work is essentially impossible without it. It’s the canonical inducer of granulocytic differentiation in myeloid biology, and any group working on transcriptional corepressor dynamics in the RAR/RXR system will reach for tretinoin eventually. We’d call it indispensable in that specific domain, and the bench value score reflects that honestly.

The evidence base is among the strongest in this library. FDA approved since 1971, multiple decades of RCTs in dermatology, and the ATRA plus arsenic trioxide standard of care in APL carries phase 3 data with long-term outcome follow-up that’s hard to argue with. The translational signal is likewise exceptional; this is a compound that clearly does what it does in real human populations, repeatedly, across multiple independent groups.

What we don’t see is a compelling novel research angle that changes the calculus. The neurological applications, retinoic acid signaling in hippocampal neurogenesis and early Alzheimer’s work, are real threads but haven’t produced signal that would justify flagging this as a target to build a new program around in 2025. The cancer chemoprevention literature is decades old and mixed. Honestly, if you already have a retinoid biology program, tretinoin is non-negotiable. If you’re asking whether it’s an exciting new target to build one around, the answer is no. The score reflects that tension directly.

Novelty

20

Mechanism promise

52

In-category differentiation

60

Evidence quality

85

Translational signal

87

Research bench value

72

Rationale Tretinoin’s low novelty (20) and well-mapped mechanistic territory drag the score despite exceptional evidence quality (85) and strong translational signal (87); its primary value in 2025 is as an indispensable bench tool for RAR/RXR biology and myeloid differentiation assays rather than a fresh frontier compound. Historically paradigm-defining in APL and photoaging but the research frontier has been mapped for decades.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous retinoid and pan-retinoic acid receptor agonist with genomic transcriptional regulation

The principal biologically active metabolite of vitamin A, functioning as a pan-RAR agonist that regulates epithelial differentiation, collagen biosynthesis, and myeloid cell maturation, with established clinical applications spanning topical dermatology, photoaging reversal, and systemic differentiation therapy of acute promyelocytic leukemia.

Abstract

Tretinoin (all-trans-retinoic acid, ATRA) is the carboxylic acid form of vitamin A and the principal endogenous ligand of the nuclear retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma), through which it regulates the transcription of over 500 target genes involved in cellular differentiation, proliferation, apoptosis, and immune modulation. First isolated and characterized in the mid-twentieth century as a metabolite of retinol, tretinoin was developed as a topical dermatological agent by Albert Kligman and James Fulton at the University of Pennsylvania in the 1960s and received United States Food and Drug Administration approval for acne vulgaris in 1971, making it the first retinoid approved for clinical use. The compound was subsequently approved for the treatment of fine facial wrinkles and mottled hyperpigmentation associated with photoaging in 1995. In the systemic setting, the landmark 1988 report by Huang and colleagues at Shanghai Second Medical University demonstrated that oral tretinoin at 45 mg/m2/day induced complete hematological remission in patients with acute promyelocytic leukemia (APL) harboring the t(15;17) translocation and the resulting PML-RAR-alpha fusion oncoprotein, establishing tretinoin as the first successful differentiation therapy in oncology and transforming APL from a rapidly fatal malignancy to one of the most curable forms of acute leukemia. The molecular pharmacology of tretinoin is mediated through ligand-dependent activation of RAR/RXR heterodimers bound to retinoic acid response elements in target gene promoters; in the unliganded state, these heterodimers recruit corepressor complexes (NCoR, SMRT) and histone deacetylases that maintain transcriptional silencing, while tretinoin binding induces conformational change, corepressor release, and coactivator recruitment with histone acetyltransferase activity, resulting in chromatin remodeling and transcriptional activation. In the dermatological context, this transcriptional program promotes keratinocyte differentiation, accelerates corneocyte shedding, inhibits comedone formation, stimulates type I procollagen synthesis, and blocks ultraviolet-induced matrix metalloproteinase activation through inhibition of activator protein 1. In APL, pharmacological concentrations of tretinoin overcome the dominant-negative transcriptional repression imposed by the PML-RAR-alpha fusion protein, driving terminal granulocytic differentiation of the leukemic clone.

Pharmacokinetics differ substantially between the topical and systemic routes. Topical application produces minimal systemic absorption, with percutaneous bioavailability estimated at less than 2 percent and negligible alteration of endogenous plasma retinoid concentrations. Oral tretinoin at the 45 mg/m2 APL dose is rapidly absorbed, reaching peak plasma concentrations of approximately 350 ng/mL (1.2 micromolar) within 1 to 2 hours, with greater than 95 percent plasma protein binding predominantly to albumin. The terminal elimination half-life is short (0.5 to 2 hours) and is dominated by oxidative metabolism through CYP26A1, CYP2C8, and CYP3A4, with a clinically significant autoinduction phenomenon: tretinoin potently upregulates CYP26A1 transcription through retinoic acid response elements in the CYP26A1 promoter, resulting in progressive acceleration of its own clearance such that plasma concentrations decline to approximately one-third of initial values within one week of continuous dosing at constant dose. This autoinduction has clinical implications for APL treatment duration and has motivated intermittent dosing schedules and combination regimens with arsenic trioxide. The compound is teratogenic through disruption of retinoic acid gradient signaling during embryogenesis, classified as FDA pregnancy category X for systemic use; topical tretinoin, by contrast, does not produce measurable increases in systemic retinoid exposure and is not associated with increased teratogenic risk in epidemiological studies, though precautionary avoidance during pregnancy is recommended. The principal systemic toxicity in APL therapy is the differentiation syndrome (formerly retinoic acid syndrome), a potentially fatal inflammatory response occurring in approximately 25 percent of treated patients and characterized by fever, dyspnea, weight gain, pulmonary infiltrates, and pleural or pericardial effusions, managed with early recognition and high-dose corticosteroids.

This monograph reviews the chemistry, structural identity, and synthesis of tretinoin; the RAR/RXR nuclear receptor pharmacology and downstream transcriptional programs; the divergent pharmacokinetics of topical and systemic administration including autoinduction; the preclinical pharmacology across dermatological, oncological, and wound-healing models; the clinical evidence base in acne, photoaging, and acute promyelocytic leukemia; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five retinoid alternatives (adapalene, tazarotene, isotretinoin, bexarotene, tamibarotene) against tretinoin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1566Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Bacoside A

Our opinion on this compoundEstablished, active research

42/100

Well-studied Ayurvedic saponin fraction with real but modest cognitive signal and a research landscape that peaked a decade ago

Look, Bacopa monnieri has been used as a cognitive aid since roughly 300 BCE, and modern scientists started characterizing bacoside A in the 1960s under the CDRI program in India. That history is context. Bacoside A is one of the better-studied herbal cognitive compounds in existence, which is a damning compliment: the bar for herbal nootropics is low, and clearing it doesn’t make this a compelling research priority right now.

The mechanism story is legitimately interesting at a surface level. Bacoside A hits cholinergic modulation, serotonergic and dopaminergic tone, oxidative stress via superoxide dismutase and catalase induction, amyloid-beta aggregation inhibition, and synaptic plasticity via BDNF-related pathways. Multi-target sounds good on paper. The problem is that none of these targets is novel, none of the binding is particularly clean, and the mixture nature of the compound (four constituent saponins: bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) makes it a frustrating probe. When you see an effect in your assay, attributing it to a specific mechanism requires a lot of extra work that a cleaner compound would spare you. Thats a real cost at the bench.

The clinical evidence base is honestly the strongest argument for continued interest here. Standardized extracts like CDRI-08 (KeenMind/Synapsa) and BacoMind have been through multiple RCTs, and the systematic reviews and meta-analyses that emerged through the 2010s and early 2020s confirm a consistent signal for memory consolidation, particularly in elderly populations and in children. The effect sizes are real but modest. The onset is slow, typically requiring 4 to 12 weeks of continuous dosing before cognitive benefits appear, which is either a feature or a bug depending on your study design. Acute mechanistic work is difficult.

Where bacoside A loses ground is differentiation. For cholinergic modulation, cleaner probes exist (huperzine A, donepezil). For antioxidant neuroprotection, more mechanistically defined compounds are available. For amyloid-beta aggregation work, the Alzheimer field has better-instrumented tools. Bacopa competes in every one of these lanes and wins none of them on precision or novelty.

What we like: the genuine clinical evidence base, the slow-build safety profile that makes long-term rodent studies tractable, and the multi-target angle that still generates publishable mechanistic questions. What we dont like: the mixture chemistry that muddies interpretation, the minimal novelty ceiling in 2026, and the fact that this is essentially the same research conversation it was a decade ago. It’s a workhorse compound that earned its place in the literature. it just doesn’t set the agenda anymore, and a serious investigator starting a new nootropic or neuroprotection program would reach for something with sharper selectivity first.

Novelty

25

Mechanism promise

42

In-category differentiation

38

Evidence quality

62

Translational signal

55

Research bench value

35

Rationale Bacoside A clears the bar on clinical evidence (multiple RCTs, meta-analyses confirming memory consolidation signal) but scores low on novelty and differentiation because the mechanism targets are all well-trodden and the mixture chemistry limits its utility as a clean research probe. Evidence quality is the standout axis; everything else pulls the score toward the low-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dammarane-type triterpenoid saponin mixture with multi-target nootropic, antioxidant, and neuroprotective activity

A mixture of dammarane-type triterpenoid saponin glycosides isolated from Bacopa monnieri (Linn.) Wettst., constituting the principal bioactive fraction responsible for the cognitive-enhancing, neuroprotective, and antioxidant pharmacology of the Ayurvedic nootropic brahmi, with demonstrated activity across cholinergic modulation, serotonergic and dopaminergic neurotransmission, amyloid-beta aggregation inhibition, and synaptic plasticity.

Abstract

Bacoside A is a mixture of four dammarane-type triterpenoid saponin glycosides (bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) isolated from the aerial parts and roots of Bacopa monnieri (Linn.) Wettst. (family Plantaginaceae, formerly Scrophulariaceae), a creeping perennial herb used in the Ayurvedic medical tradition for over three millennia under the name brahmi as a medhya rasayana (intellect-rejuvenating) agent. The bacoside A fraction, typically comprising 40 to 55 percent of standardized Bacopa monnieri extracts by weight, is the principal pharmacologically active constituent and the basis of standardization for all clinically studied Bacopa preparations including CDRI-08 (KeenMind, Synapsa), BacoMind, and BaCognize. The aglycone cores of the constituent saponins are jujubogenin and pseudojujubogenin, linked to arabinose-glucose trisaccharide chains that modulate solubility, bioavailability, and receptor interaction profiles.

The pharmacology of bacoside A is multi-target and operates through at least five characterized mechanisms: (1) enhancement of cholinergic neurotransmission through upregulation of choline acetyltransferase activity and inhibition of acetylcholinesterase; (2) modulation of serotonergic neurotransmission through interaction with 5-HT1A and 5-HT2C receptor subtypes, with downstream effects on anxiety, mood, and cognitive flexibility; (3) dopaminergic modulation in prefrontal and hippocampal circuits; (4) potent antioxidant neuroprotection through scavenging of reactive oxygen species, suppression of lipid peroxidation, and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase; and (5) inhibition of amyloid-beta peptide fibrillation and cytotoxicity through direct interaction with amyloid-beta (1-42), reducing aggregation and membrane disruption in neuronal cell models. Additional mechanisms include enhancement of brain-derived neurotrophic factor (BDNF) expression, promotion of hippocampal dendritic branching and synaptic density in the CA1 and CA3 regions, and modulation of GABAergic neurotransmission.

The clinical evidence base for Bacopa monnieri standardized to bacoside A content comprises at least nine randomized, double-blind, placebo-controlled trials in healthy adults, elderly populations, and children, conducted principally at Swinburne University of Technology (Stough laboratory), the University of Wollongong (Roodenrys laboratory), and multiple Indian academic medical centers. The consistent finding across these trials is statistically significant improvement in speed of visual information processing, learning rate, memory consolidation, and delayed recall after 8 to 12 weeks of oral administration at 300 to 450 mg per day of extract standardized to 50 to 55 percent bacosides, with secondary anxiolytic effects and reduction in state anxiety scores. Effect onset requires sustained administration; acute single-dose cognitive enhancement has not been reliably demonstrated. A 2012 systematic review by Pase et al. confirmed the cognitive-enhancing effects across six qualifying trials and identified memory consolidation as the most reproducible endpoint.

Pharmacokinetic characterization of isolated bacoside A in humans remains incomplete. In silico ADMET analyses of the constituent saponins and their aglycone derivatives indicate favorable predicted oral absorption for the aglycones (jujubogenin, pseudojujubogenin), with central nervous system drug-like properties including adequate predicted blood-brain barrier penetration. The intact glycosides are poorly water-soluble and are believed to undergo gastrointestinal hydrolysis to active aglycone metabolites, a transformation consistent with the delayed onset of clinical effect observed in human trials. Hepatic metabolism involves cytochrome P450 enzymes; Bacopa monnieri standardized extract has been demonstrated to inhibit CYP3A4, CYP2C9, CYP2C19, and CYP1A2 in vitro at estimated gut concentrations, with potential for clinically significant herb-drug interactions.

The compound is well tolerated at standard doses (300 to 600 mg per day of standardized extract). The principal adverse events are mild gastrointestinal disturbances (nausea, abdominal cramps, increased stool frequency) that typically attenuate with continued use. No hepatotoxicity has been reported despite widespread use. A thyroid-stimulating effect (elevation of serum T4) has been characterized in animal studies and warrants caution in individuals with thyroid disorders. This monograph reviews the chemistry, biosynthesis, and structural characterization of bacoside A; the multi-target molecular pharmacology; the pharmacokinetic profile; the preclinical neuroprotective and cognitive evidence; the clinical trial evidence base; sourcing and quality verification for standardized extracts; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five alternative nootropic candidates (Hericium erinaceus, Ginkgo biloba EGb 761, phosphatidylserine, alpha-GPC, and citicoline) against bacoside A on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1614Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Cycloastragenol

Our opinion on this compoundEstablished, active research

51/100

The canonical small-molecule telomerase activator, mechanistically interesting but commercially entangled and evidence-thin outside TA-65 consortium studies

Look, cycloastragenol has one genuinely interesting story and it’s tied up in telomerase biology. The Geron screen in the early 2000s that pulled this out of Astragalus extract was a real finding – a small molecule that upregulates hTERT expression and nuclear translocation via the Hsp90 chaperone complex is not something you see every day, and the CREB signaling axis involvement gives it mechanistic depth that the typical single-receptor compound doesn’t have.

The problem is that most of this story is now 20 years old. TA-65 commercialized it early, which means the compound has been living in that uncomfortable space between nutraceutical and research tool for a long time. That commercial context has shaped the evidence base in ways that complicate evaluation: the Salvador 2016 RCT is genuinely well-designed (double-blind, placebo-controlled, 117 CMV-positive subjects), and the telomere lengthening signal is statistically solid (530 plus or minus 180 bp in the low-dose group, p equals 0.005, vs. active shortening in placebo). Thats real. But the entire clinical infrastructure runs through TA-65 studies, which creates consortium-dependence that limits independent confirmation.

What we like here is the expanding secondary pharmacology. The preclinical work on NF-kB and pyroptosis pathway inhibition, Nrf2/HO-1 activation, SIRT1 upregulation, BDNF/TrkB/CREB signaling in neuronal models – this isnt hand-waving. These are distinct mechanisms being characterized across multiple labs, and the breadth of activity suggests this compound genuinely touches biology that matters. The cardioprotective autophagy angle through AKT1-RPS6KB1 inhibition is a relatively fresh preclinical thread that hasn’t been fully exploited by independent groups yet.

The oncogenesis concern deserves honest treatment: it hasn’t materialized in preclinical cancer bioassays or in 12-month clinical observation, but activating hTERT pharmacologically is a mechanism that warrants continued surveillance. That’s a legitimate asterisk on the translational story, and it’s probably the reason the clinical program hasn’t accelerated the way a clean safety profile might otherwise allow.

As a bench tool, cycloastragenol has a specific and genuine use case. If you’re working on replicative senescence, telomere dynamics, or aging-related inflammatory signaling in primary human cells, this is one of very few small molecules that can pharmacologically activate telomerase in CD4-positive and CD8-positive T lymphocytes and fibroblasts. The bioavailability post-hydrolysis (approximately 25.7% oral in rat models vs. 2.2% for the astragaloside IV parent compound) makes it tractable for in vivo work, though aggressive hepatic first-pass metabolism – only 8.2% remaining after 30 minutes in human liver microsomes – is a real constraint on systemic exposure planning.

Differentiation from alternatives is real but narrow. It essentially defines the small-molecule telomerase activator category by virtue of being the only validated entry in serious research use. That’s best-in-class by default more than by competition. The TA-65 association means sourcing is straightforward, but it also means the compound carries commercial noise that independent investigators have to actively work around when designing studies.

Novelty

38

Mechanism promise

58

In-category differentiation

62

Evidence quality

48

Translational signal

45

Research bench value

55

Rationale Cycloastragenol defines the small-molecule telomerase activator category and has expanding secondary pharmacology across senescence, neuroinflammation, and cardioprotection; however, a 20-year commercial history through TA-65 has concentrated the clinical evidence base in a single-consortium context with small N, keeping evidence and translational scores well below the threshold for a higher category placement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Lanostane-type tetracyclic triterpenoid sapogenin with telomerase-activating, anti-inflammatory, and antioxidant activity

A naturally occurring triterpenoid aglycone derived from Astragalus membranaceus, identified as the bioactive sapogenin of astragaloside IV and the principal small-molecule telomerase activator in the TA-65 formulation, with expanding preclinical evidence in anti-inflammatory, neuroprotective, cardioprotective, and anti-senescence applications.

Abstract

Cycloastragenol (CAG) is a lanostane-type tetracyclic triterpenoid sapogenin obtained by acid or enzymatic hydrolysis of astragaloside IV, the principal bioactive saponin of Astragalus membranaceus (Huangqi), a plant with extensive use in traditional Chinese medicine. The compound gained prominence following a systematic screen of natural product libraries at Geron Corporation in the early 2000s that identified it as a small-molecule activator of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase. This discovery led to the development and commercialization of TA-65, a proprietary cycloastragenol-containing nutraceutical formulation marketed by T.A. Sciences for telomere health and anti-aging applications. The telomerase-activating mechanism involves upregulation of hTERT gene expression, enhanced nuclear localization of the hTERT protein via upregulation of the Hsp90 chaperone complex, and activation of the cAMP response element binding protein (CREB) signaling axis. At the cellular level, cycloastragenol activates telomerase in multiple cell types including peripheral blood mononuclear cells, CD4-positive and CD8-positive T lymphocytes, fibroblasts, and neuronal cells, with functional consequences including telomere elongation, reduced replicative senescence, and enhanced proliferative capacity. A 2016 randomized, double-blind, placebo-controlled clinical trial of TA-65 in 117 cytomegalovirus-positive subjects aged 53 to 87 years demonstrated dose-dependent telomere lengthening in the low-dose group (530 plus or minus 180 base pairs; p equals 0.005) over 12 months, with the placebo group losing telomere length (290 plus or minus 100 base pairs; p equals 0.01). The compound additionally exhibits pharmacological activities independent of the telomerase mechanism. Preclinical studies have characterized anti-inflammatory effects through inhibition of NF-kappaB signaling and pyroptosis pathways; neuroprotective activity through upregulation of SIRT1 expression, activation of the Nrf2/HO-1 pathway, and promotion of BDNF/p-TrkB/CREB signaling; cardioprotective effects through promotion of myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling; anti-fibrotic activity in hepatic and pulmonary models; and antioxidant effects through activation of the Nrf2/ARE transcriptional pathway. Pharmacokinetics in the rat model show oral bioavailability of approximately 25.7 percent following acid hydrolysis-mediated absorption, substantially higher than the parent compound astragaloside IV (2.2 percent), with extensive first-pass hepatic metabolism limiting systemic exposure. In human liver microsomes, only 8.2 percent of cycloastragenol remained after 30 minutes of incubation, indicating rapid phase I metabolism. A 91-day subchronic toxicity study in rats at doses up to 150 mg/kg/day by oral gavage produced no treatment-related mortalities, no cardiac effects, and no evidence of genotoxicity or carcinogenicity. Clinical safety data from TA-65 studies over 12 months of supplementation report no serious adverse events, with mild gastrointestinal discomfort as the principal dose-dependent adverse effect. The theoretical concern of telomerase activation promoting oncogenesis has not been substantiated in preclinical cancer bioassays or in clinical observation, though the mechanism warrants continued surveillance. This monograph reviews the chemistry and structural classification of cycloastragenol; its discovery as a telomerase activator and subsequent commercial development; the molecular pharmacology across telomerase, anti-inflammatory, neuroprotective, and cardioprotective pathways; the pharmacokinetic profile including metabolism and bioavailability; the preclinical evidence base; the clinical evidence from TA-65 trials and related human studies; sourcing, quality verification, and reconstitution considerations; stack interactions; adverse events and safety signals; and a comparative assessment of five telomerase-modulating or astragalus-derived compounds against cycloastragenol on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1611Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Eplerenone

Our opinion on this compoundEstablished workhorse

46/100

Approved selective MRA with landmark trial heritage, now largely superseded by non-steroidal successors in active research

Look, eplerenone’s story is the story of a compound that did exactly what it was supposed to do and then got left behind by the field it helped create. The 9-alpha,11-alpha-epoxy modification was a genuinely clever piece of medicinal chemistry. Spironolactone’s gynecomastia problem was real, the aldosterone-driven cardiac remodeling hypothesis was underappreciated in the 1980s, and Searle’s SC-66110 program produced a meaningfully cleaner pharmacological profile: 500- to 800-fold selectivity advantage over androgen and progesterone receptors versus the parent scaffold. That mattered.

EPHESUS (2003) and EMPHASIS-HF (2011) are landmark cardiovascular trials. Meaningful all-cause mortality benefit in post-myocardial infarction heart failure and in systolic heart failure respectively, replicated across large populations, published in high-impact journals, FDA approved. The clinical evidence quality here is genuinely high and the translational arrow is solid. We’re not dismissing those results. But from a research-merit standpoint, all of that is fully banked. The questions eplerenone could answer have been answered. MR antagonism in cardiac fibrosis, aldosterone escape, sodium retention pathways – textbook at this point.

Here’s the thing: if you’re running a bench program to probe mineralocorticoid receptor biology in 2025, you’re not reaching for eplerenone as your primary tool. Finerenone (BAY 94-8862, Kerendia) has a non-steroidal scaffold with a different receptor binding mode, distinct genomic vs. non-genomic downstream effects, and has been the subject of two major DKD outcome trials (FIDELIO-DKD and FIGARO-DKD) that opened entirely new indication territory. Esaxerenone is active in Japan. Ocedurenone and several pipeline non-steroidals are pushing the MR antagonist class into novel mechanistic territory. Eplerenone isnt leading any of those conversations.

Bench utility exists but its limited. Eplerenone is commercially available, reasonably selective, and useful for dissecting aldosterone-dependent versus aldosterone-independent effects in rodent cardiac and renal fibrosis models. The selectivity profile is cleaner than spironolactone for experimental designs where androgen receptor confound is a concern. But for most purposes spironolactone or finerenone serve the same probe function, and the eplerenone literature for those applications is thoroughly mined. Theres very little methodological white space left here.

What we’re left with is an approved drug with an excellent evidence pedigree that has largely fulfilled its research purpose. High marks for evidence quality and translational signal. Low marks for novelty, mechanism frontier, and differentiation from better successors. The field built on eplerenone’s foundation and moved on. For investigators actively working the MR biology or cardiorenal space, finerenone is the more compelling object of study right now by a meaningful margin. Eplerenone as a comparator arm in finerenone trials? Absolutely. Eplerenone as the primary research target in 2025? Hard to justify.

Novelty

22

Mechanism promise

30

In-category differentiation

36

Evidence quality

75

Translational signal

78

Research bench value

48

Rationale Strong evidence (EPHESUS, EMPHASIS-HF) and solid translational signal lift the calculation, but novelty and mechanism scores drag hard: the compound is 24 years post-approval, the selectivity-over-spironolactone story is completely banked, and finerenone plus the non-steroidal scaffold class have taken over the active MRA research narrative. Overall of 46 reflects a well-validated but largely exhausted research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective steroidal mineralocorticoid receptor antagonist with 9-alpha,11-alpha-epoxy modification conferring high receptor selectivity over androgen and progesterone receptors

A selective aldosterone antagonist derived from the spironolactone scaffold through introduction of a 9-alpha,11-alpha-epoxy group, developed across four pharmaceutical sponsors over two decades and validated in landmark heart failure and post-myocardial infarction trials as the first mineralocorticoid receptor antagonist with clinically meaningful selectivity over sex steroid hormone receptors.

Abstract

Eplerenone is a steroidal mineralocorticoid receptor (MR) antagonist and the second agent approved in this pharmacological class, reaching United States Food and Drug Administration registration in 2002 (marketed as Inspra) approximately four decades after the introduction of spironolactone, the first-generation nonselective aldosterone blocker. The compound is distinguished from spironolactone by the presence of a 9-alpha,11-alpha-epoxy bridge and a 17-alpha-carbomethoxy substituent, structural modifications that confer approximately 20- to 40-fold lower binding affinity at the mineralocorticoid receptor but approximately 500- to 800-fold greater selectivity over the androgen, progesterone, and glucocorticoid receptors. This selectivity profile eliminates the gynecomastia, breast pain, menstrual irregularity, and sexual dysfunction that limit spironolactone tolerability in chronic cardiovascular and renal indications.

The clinical evidence base for eplerenone rests on two landmark randomized controlled trials. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), published in 2003 in the New England Journal of Medicine, enrolled 6,632 patients with left ventricular dysfunction (ejection fraction 40 percent or less) 3 to 14 days after acute myocardial infarction and demonstrated that eplerenone 25 to 50 mg daily reduced all-cause mortality by 15 percent (relative risk 0.85; 95 percent confidence interval 0.75 to 0.96) and heart failure hospitalization by 15 percent compared to placebo on top of optimal medical therapy. The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), published in 2011 in the New England Journal of Medicine, enrolled 2,737 patients with chronic systolic heart failure (ejection fraction 35 percent or less) and New York Heart Association class II symptoms and demonstrated that eplerenone reduced the composite of cardiovascular death and heart failure hospitalization by 37 percent (hazard ratio 0.63; 95 percent confidence interval 0.54 to 0.74). These trials established eplerenone as a guideline-recommended therapy in heart failure with reduced ejection fraction and in post-myocardial infarction left ventricular dysfunction across all major international cardiovascular society guidelines.

Eplerenone is approved in the United States for hypertension and for heart failure following myocardial infarction with left ventricular dysfunction. The compound is also approved in the European Union, Japan, and multiple additional jurisdictions for heart failure with reduced ejection fraction. The pharmacokinetic profile is characterized by rapid oral absorption (time to maximum plasma concentration approximately 1.5 hours), absolute bioavailability of approximately 69 percent, elimination half-life of 4 to 6 hours, and predominant hepatic metabolism by cytochrome P450 3A4 (CYP3A4) with contributions from CYP3A5. The principal adverse event is dose-dependent hyperkalemia, occurring in approximately 5 to 10 percent of treated patients depending on baseline renal function and concurrent renin-angiotensin-aldosterone system blockade; the risk is substantially increased in patients with estimated glomerular filtration rate below 30 mL/min/1.73 m2 and in those with serum potassium above 5.0 mEq/L at baseline. The absence of clinically meaningful gynecomastia (0.7 percent versus 9 to 10 percent for spironolactone in controlled trials) is the principal tolerability advantage.

This monograph reviews the chemistry, synthesis, and structural pharmacology of eplerenone; the molecular pharmacology at the mineralocorticoid receptor in detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology in cardiac fibrosis, remodeling, and inflammatory models; the clinical evidence base across heart failure, post-myocardial infarction, hypertension, and emerging renal indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications with emphasis on CYP3A4-mediated drug-drug interactions and potassium homeostasis; adverse-event signal with focus on hyperkalemia risk stratification; and a structured comparative assessment of five mineralocorticoid receptor antagonists (spironolactone, finerenone, esaxerenone, canrenone, ocedurenone) against eplerenone on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1564Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Tributyrin

Our opinion on this compoundEstablished, active research

46/100

Best butyrate prodrug with composite HDAC and GPCR pharmacology, but a mature concept with thin clinical evidence

Look, tributyrin has a genuinely interesting angle, and we dont want to bury that. The core problem it solves is real: free butyric acid smells terrible, gets cleared hepatically before it can do much, and sodium butyrate isn’t much better as a delivery form. Tributyrin sidesteps all of that. As a triglyceride ester, it survives gastric passage intact, gets hydrolyzed intracellularly by lipases, and releases three butyrate equivalents per molecule. That’s a pharmacologically meaningful improvement over anything else in the butyrate delivery category, and the comparator landscape here is weak enough that tributyrin genuinely defines it.

The composite pharmacology is what keeps this compound interesting. Butyrate itself hits at least three distinguishable targets: Class I/II HDAC inhibition at the epigenetic level, agonism at GPR109A (HCAR2) which has its own anti-inflammatory and niacin-receptor biology, and activity at GPR41/43 (free fatty acid receptors) relevant to gut hormone signaling and colonocyte metabolism. That’s not single-receptor agonism in a saturated class. We think the HDAC inhibition angle is particularly underappreciated outside oncology circles, especially now that the intestinal barrier and metabolic inflammation literature is generating real interest in epigenetic modulation of epithelial function.

Here’s the thing though: the Phase I oncology trials that put tributyrin on the map ran in the late 1990s and early 2000s. They established tolerability and some pharmacokinetic parameters, but they didnt generate the kind of efficacy signal that pushes a compound into Phase 2 in oncology. The Parkinson’s angle is genuinely novel and interesting, but it’s early and thin. Most of the heavy lifting in the literature is still preclinical, still in rodent gut models, still using dose ranges that don’t map cleanly to any human exposure. The clinical story is real but incomplete, and thats been true for twenty-five years now.

For bench investigators working on GI barrier biology, HDAC biology in epithelial cells, or metabolic inflammation, tributyrin is a legitimately useful probe. It gives you systemic butyrate exposure in a way sodium butyrate cant, and the lipase-mediated intracellular release makes it interesting for mechanistic dissection. We’d reach for it in a heartbeat for intestinal organoid work or in vivo colonocyte HDAC studies. Outside those specific niches, though, the novelty floor is low. The butyrate field is not exactly underexplored. Tributyrin is the best tool in a well-mapped drawer, which earns it a solid but unspectacular place in the library.

Novelty

28

Mechanism promise

52

In-category differentiation

58

Evidence quality

45

Translational signal

42

Research bench value

58

Rationale Tributyrin earns its place as the cleanest oral butyrate delivery vehicle, outperforming sodium butyrate on bioavailability, odor, and three-equivalent release; however, the underlying butyrate biology is decades old, Phase I oncology data never advanced to meaningful efficacy trials, and the compound sits in a well-mapped mechanistic neighborhood rather than on any real frontier. Scored as established-active rather than novel-promising because neither the chemistry nor the indication landscape has meaningfully shifted since the 1990s program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Triglyceride prodrug of butyric acid with histone deacetylase inhibitory activity

A glycerol tributyrate ester functioning as a stable, orally bioavailable prodrug of butyric acid, distinguished from other butyrate delivery forms by its resistance to gastric degradation, intracellular lipase-mediated release of three butyrate equivalents, and HDAC-inhibitory activity supporting applications in oncology chemoprevention, intestinal barrier maintenance, hepatoprotection, metabolic inflammation, and skeletal muscle differentiation.

Abstract

Tributyrin (glycerol tributyrate, CAS 60-01-5) is the 1,2,3-tributanoyl ester of glycerol and the principal triglyceride prodrug of butyric acid studied in human clinical pharmacology and preclinical oncology. Classified by the United States Food and Drug Administration as Generally Recognized as Safe (GRAS) for food use, tributyrin is a naturally occurring lipid constituent of bovine milk fat and honey that has attracted sustained research interest as a vehicle for delivering pharmacologically active butyrate concentrations to systemic circulation and to the colonic epithelium, overcoming the rapid first-pass hepatic clearance, objectionable odor, and poor oral bioavailability that limit the therapeutic application of free butyric acid and its sodium salt.

The molecular pharmacology of tributyrin is mediated through its hydrolytic product, butyrate, a four-carbon short-chain fatty acid that operates through at least three characterized molecular mechanisms: inhibition of class I and class II histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3; agonism at the G-protein-coupled receptor GPR109A (also designated HCAR2 or HM74a), the niacin receptor expressed on colonocytes, adipocytes, and immune cells; and agonism at the free fatty acid receptors GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells and immune cells. The HDAC-inhibitory activity produces histone hyperacetylation, chromatin remodeling, and consequent transcriptional activation of tumor suppressor genes (p21WAF1/CIP1, BAX, p53), cell cycle arrest proteins, and differentiation-associated gene programs in neoplastic cells. The GPR109A agonism mediates anti-inflammatory signaling through suppression of NF-kappaB-dependent proinflammatory cytokine production and through promotion of regulatory T-cell and M2-macrophage phenotypes in adipose tissue and intestinal lamina propria.

Two Phase I clinical trials in patients with advanced solid tumors have characterized the human pharmacology of tributyrin. The Conley et al. (1998) study administered tributyrin at 50 to 400 mg/kg/day orally to 13 patients and demonstrated dose-proportional plasma butyrate concentrations reaching 0 to 0.45 mM, with no dose-limiting toxicity. The Edelman et al. (2003) study administered tributyrin at 150 to 200 mg/kg three times daily to 20 patients with advanced solid tumors and achieved median plasma butyrate concentrations of 52 micromolar with considerable interpatient variability; escalation was halted at 200 mg/kg three times daily owing to the large number of capsules required rather than to toxicity. Both trials confirmed that tributyrin is well tolerated, with mild gastrointestinal complaints (nausea, eructation, diarrhea) as the principal adverse events.

Preclinical pharmacology spans oncology, gastroenterology, hepatology, metabolic disease, and muscle biology. In oncology, tributyrin induces differentiation, growth arrest, and apoptosis in human prostate cancer (PC3, LNCaP, TSU-Pr1), colon cancer (HT-29, Caco-2), breast cancer (MCF-7), and leukemia cell lines at concentrations of 0.1 to 4 mM, and suppresses hepatocarcinogenesis in the resistant hepatocyte rat model through p53 acetylation and activation of the p53 apoptotic signaling pathway. In gastroenterology, tributyrin maintains intestinal tight junction integrity, reduces antibiotic-induced intestinal injury in combination with Lactobacillus GG, and mitigates chronic-binge ethanol-induced intestinal barrier disruption and liver injury. In metabolic disease, tributyrin attenuates obesity-associated inflammation, improves insulin responsiveness, and reduces hepatic triglyceride accumulation through a GPR109A-dependent mechanism. In muscle biology, dietary tributyrin promotes satellite cell terminal differentiation through HDAC inhibition and epigenetic priming, producing measurable increases in muscle fiber cross-sectional area in neonatal piglet models.

This monograph reviews the chemistry, synthesis, and physicochemical properties of tributyrin; the three-arm molecular pharmacology (HDAC inhibition, GPR109A agonism, FFAR agonism); the human pharmacokinetic record from Phase I oncology trials; the preclinical evidence base across oncology, gastrointestinal, hepatoprotective, metabolic, and muscle biology applications; sourcing and quality verification for research use; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative butyrate delivery forms against tributyrin on five competency standards (bioavailability, effect size, delivery specificity, tolerability profile, and overall validation). The compound is not approved as a drug by any regulatory authority. It is sold as a dietary supplement and as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1609Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Zelquistinel

Our opinion on this compoundNovel, promising

69/100

Oral NMDA PAM at a unique extracellular site, no psychotomimetic liability, Phase 2b in MDD underway

Look, the NMDA receptor story for depression has been a graveyard of good ideas. Rapastinel showed Phase 2 signal then failed in Phase 3. Ketamine works but requires clinic administration and psychotomimetic monitoring that limits practical use. Zelquistinel is trying to solve both of those problems simultaneously, and the mechanism it’s using to do it is genuinely interesting in a way that warrants serious attention.

The core story is about allosteric modulation at a distinct extracellular site, independent of the classical glutamate-binding site and the glycine co-agonist site. The proximal effect is reduction of calcium-dependent inactivation, which means the receptor stays active longer under calcium load. This is a fundamentally different approach to NMDA pharmacology than anything in clinical use. What we like is that the functional profile in preclinical work, including rapid antidepressant-like effects across multiple paradigms, separates from psychotomimesis at relevant concentration ranges. Thats the exact hole the rapastinel and apimostinel programs were trying to fill, and zelquistinel gets you there with an oral pill rather than a clinic-administered infusion.

The oral bioavailability story is a real advance. Rapastinel was intravenous; apimostinel was peptide-based with constrained oral exposure. The spirocyclic 2,5-diazaspiro[3.4]octane beta-lactam scaffold that defines zelquistinel hits near-complete bioavailability in preclinical species, half-life in the 1.2 to 2.1 hour range, and roughly 1000-fold greater potency than rapastinel on a weight basis. For bench work, that means you can run clean oral chronic-dosing paradigms and longitudinal behavioral studies that simply weren’t practical with the earlier peptide formats. The NR2A, NR2B, and NR2C subtype selectivity profile also gives investigators a way to probe subunit-specific contributions to synaptic plasticity that ketamine can’t offer cleanly.

Bhatt et al. 2022 in the International Journal of Neuropsychopharmacology is the canonical mechanism characterization, and the preclinical literature is solid multi-lab work. The Phase 2a in MDD showed a real signal. Phase 2b is ongoing under Syndeio Biosciences. FDA Fast Track designation is on record. The honest constraint is that we’re not at Phase 3 yet, and replication outside the platform-originating consortium is thin. The rapastinel Phase 3 failure is not zelquistinel’s failure, but it does lower prior confidence that Phase 2a MDD signal in this class converts.

We think this is the most mechanistically interesting NMDA modulator currently in Phase 2 development. Its differentiation from esketamine is structural and functional, not cosmetic. The score reflects a compound that earns high marks on novelty and mechanism but sits at a realistic evidence stage where the clinical verdict is still genuinely open.

Novelty

70

Mechanism promise

82

In-category differentiation

76

Evidence quality

55

Translational signal

55

Research bench value

68

Rationale Zelquistinel earns high novelty and mechanism scores for being the first orally bioavailable small-molecule NMDA PAM acting at an extracellular site independent of the glycine co-agonist site, cleanly separated from channel-blocker psychotomimesis. Evidence and translational scores are anchored by a real Phase 2a signal but held back by incomplete Phase 2b data and the long shadow of rapastinel’s Phase 3 failure on class confidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Novel positive allosteric modulator of the N-methyl-D-aspartate receptor acting at a unique extracellular binding site independent of the glycine co-agonist site

A third-generation, orally bioavailable spirocyclic beta-lactam NMDA receptor modulator developed from the rapastinel peptidomimetic platform, distinguished by nanomolar positive allosteric modulation of NR2A-, NR2B-, and NR2C-containing NMDA receptors through reduction of calcium-dependent inactivation, producing rapid and sustained antidepressant-like effects without psychotomimetic liability.

Abstract

Zelquistinel (GATE-251, formerly AGN-241751) is a novel, orally bioavailable, small-molecule positive allosteric modulator of the N-methyl-D-aspartate (NMDA) glutamate receptor, currently in Phase 2b clinical development for major depressive disorder (MDD) under the sponsorship of Syndeio Biosciences (operating as Gate Neurosciences). The compound is the third-generation successor to the tetrapeptide rapastinel (GLYX-13) and the dipeptide apimostinel (NRX-1074), sharing a common mechanism of NMDA receptor positive modulation but replacing the peptide scaffold with a spirocyclic 2,5-diazaspiro[3.4]octane (beta-lactam) core that confers oral bioavailability approaching 100 percent in preclinical species, a plasma half-life of approximately 1.2 to 2.1 hours, and approximately 1000-fold greater potency than rapastinel on a weight basis.

Zelquistinel binds to a unique extracellular site on the NMDA receptor that is distinct from the glutamate agonist site, the glycine co-agonist site, the phencyclidine channel-blocking site, and the polyamine modulatory site. The compound does not displace radioligands at any of these four canonical sites and shows no significant activity across a panel of 80 receptors, ion channels, and monoamine transporters. Mechanistically, zelquistinel acts through a long-distance allosteric pathway: extracellular binding reduces intracellular calcium-dependent inactivation (CDI) of the NMDA receptor channel, thereby enhancing NMDA receptor current in an activity-dependent manner. This mechanism has been demonstrated through experiments showing that replacement of the intracellular calcium chelator EGTA with the fast chelator BAPTA abolishes zelquistinel potentiation, and that removal of the NR1 C-terminal intracellular domain or infusion of calmodulin-blocking peptide similarly eliminates the modulatory effect. Subtype selectivity studies reveal potent enhancement at NR2A-containing (EC50 approximately 9.9 nM) and NR2C-containing (EC50 approximately 9.7 nM) receptors, with a larger ceiling enhancement at NR2B-containing receptors (EC50 approximately 35.0 nM) and no effect at NR2D-containing receptors.

The pharmacological profile produces a characteristic biphasic, inverted-U dose-response relationship: potentiation of NMDA receptor-mediated calcium influx at concentrations of 0.3 to 60 nM and mild inhibition at concentrations exceeding 100 nM. In preclinical behavioral models, single oral doses of zelquistinel at 30 micrograms per kilogram produce rapid antidepressant-like effects in the forced swim test (onset within one hour) that are sustained for more than seven days, and rescue social approach behavior in the chronic social defeat model at efficacy comparable to ketamine at 10 mg/kg subcutaneous. The compound enhances long-term potentiation (LTP) in both medial prefrontal cortex and hippocampal Schaffer collateral-CA1 pathways, with metaplastic enhancement persisting for at least two weeks after a single dose. Critically, zelquistinel produces no motor impairment on the rotarod test at doses 100-fold above the antidepressant-effective dose and no psychotomimetic symptoms as measured by validated clinical scales in human subjects.

In Phase 1 clinical evaluation, single ascending oral doses from 100 micrograms to 50 mg were well tolerated in 60 healthy volunteers, with dose-proportional pharmacokinetics, rapid absorption, significant cerebrospinal fluid penetration, and no clinically significant adverse events, vital sign changes, electrocardiographic abnormalities, or psychotomimetic symptoms. A Phase 2a exploratory trial in 251 patients with major depressive disorder demonstrated statistically significant reductions in Montgomery-Asberg Depression Rating Scale (MADRS) scores at the two highest once-weekly oral doses (reductions of 9.5 and 10.6 points versus 7.7 points with placebo at week three). The U.S. Food and Drug Administration granted Fast Track designation for zelquistinel in MDD in July 2018. As of the date of this monograph, a Phase 2b confirmatory trial is actively recruiting under Syndeio Biosciences sponsorship. Additional preclinical research has demonstrated durable relief of core behavioral deficits in three mouse models of autism spectrum disorder, and dose-dependent reversal of phencyclidine-induced hyperlocomotion, expanding the potential therapeutic scope beyond depression.

This monograph reviews the chemistry, structural class, and synthesis of zelquistinel; the dual extracellular-intracellular allosteric mechanism in molecular and electrophysiological detail; the comprehensive preclinical and human pharmacokinetic record; the clinical evidence base in major depressive disorder; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five NMDA receptor-targeting antidepressant candidates (rapastinel, apimostinel, esketamine, REL-1017, and AV-101) against zelquistinel on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1569Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Cytoflavin

Our opinion on this compoundSingle-lab provenance

39/100

A coherent mitochondrial rescue combination undermined by generic components and single-ecosystem evidence

The core appeal of Cytoflavin is straightforward and real: supply four rate-limiting metabolic substrates simultaneously to stressed mitochondria, bypassing the NAD-dependent Krebs cycle steps that fail first under ischemia. That’s a legitimate pharmacological idea. Succinic acid feeds directly into Complex II while riboflavin provides the FAD prosthetic group required to run it; nicotinamide replenishes the NAD+ pool hammered by PARP activation during ischemic injury; and inosine supports purine salvage and ATP resynthesis. Each component addresses a documented bottleneck in ischemic energy failure, and the rationale for combining them in fixed proportion is coherent, not marketing fiction.

Here’s the thing though: none of these are new ideas, and none of these are novel compounds. Succinic acid is a Krebs cycle intermediate that biology settled on roughly two billion years ago. Riboflavin is vitamin B2. Nicotinamide has been in clinical medicine for decades. Inosine is a purine nucleoside studied in stroke contexts since at least the early 1970s. What POLYSAN built is a combination product with a specific fixed ratio and an internal clinical trial program, not a new compound with new chemistry. The succinate/Complex II bypass story does have genuine independent support in the ischemia-reperfusion literature, particularly from the Murphy and Chouchani group work on succinate accumulation and mitochondrial RET, but that literature doesn’t depend on or validate Cytoflavin specifically.

The evidence base is the other central problem. Cytoflavin has genuine clinical trials behind it: the CYLINDER study in diabetic polyneuropathy, CITADEL in post-COVID rehabilitation, multiple acute ischemic stroke RCTs, postoperative cognitive decline work, elderly patient series. Thats a real body of human-subject research, and we don’t want to dismiss it entirely. But its almost entirely generated within the Russian research ecosystem, primarily by investigators associated with POLYSAN, and the product isnt registered by FDA, EMA, TGA, MHRA, or Health Canada. This is structurally identical to the Cerebrolysin problem: decades of Eastern European literature that has not replicated well outside its originating context, a manufacturer who controls the clinical program, and no independent regulatory body that has reviewed the full dataset.

For bench work, the combination format is a liability rather than an asset. A researcher interested in the succinate/Complex II axis would use pure succinic acid, diethyl succinate, or cell-permeable succinate analogs like NV118 to control the intervention precisely. A researcher studying NAD+ biology would use NMN, NR, or nicotinamide directly. No one designing a mechanistic experiment reaches for a fixed four-component tablet. What we like: the underlying mitochondrial energy rescue biology is real and worth studying, and the product has more pharmacological logic than most Russian neuroprotectants. What we don’t like: the individual components are too generic, the evidence too geographically concentrated, and the combination too coarse for mechanistic investigation. The score reflects a compound with honest mechanistic rationale and a genuine trial record, restrained by the endemic problems of single-ecosystem evidence and research-commodity ingredients.

Novelty

32

Mechanism promise

50

In-category differentiation

38

Evidence quality

35

Translational signal

42

Research bench value

30

Rationale Scores are driven up by a genuinely clever composite mechanism addressing four documented rate-limiting steps in ischemic energy failure, but suppressed hard by the generic nature of all four individual ingredients and an evidence base that is almost entirely Russian/POLYSAN-origin and unreplicated in Western regulatory or academic settings. The fixed-combination format actively reduces bench utility versus pure component analogs, and the single-manufacturer trial ecosystem shares the core Cerebrolysin problem.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Fixed-dose combination metabolic cytoprotectant comprising succinic acid, inosine, nicotinamide, and riboflavin for mitochondrial energy rescue and antihypoxant neuroprotection

A four-component metabolic combination drug developed by POLYSAN Ltd. that supplies Krebs cycle substrate, purine nucleoside, NAD+ precursor, and FAD cofactor to restore aerobic energy production in ischemic, hypoxic, and neurodegenerative tissue.

Abstract

Cytoflavin is a fixed-dose combination metabolic agent comprising succinic acid (the principal mass component and Krebs cycle substrate), inosine (a purine nucleoside and precursor to adenine nucleotides), nicotinamide (the amide form of vitamin B3 and precursor to nicotinamide adenine dinucleotide), and riboflavin (vitamin B2, the precursor to flavin adenine dinucleotide and flavin mononucleotide). Developed and manufactured by POLYSAN Scientific and Technological Pharmaceutical Company (Saint Petersburg, Russia), the product is formulated as enteric-coated tablets (300 mg succinic acid, 50 mg inosine, 25 mg nicotinamide, 5 mg riboflavin per tablet) and as a concentrate for intravenous infusion (1000 mg succinic acid, 200 mg inosine, 100 mg nicotinamide, 20 mg riboflavin sodium phosphate per 10 mL ampoule, with meglumine and sodium hydroxide as excipients). The pharmacological rationale is the simultaneous provision of four complementary metabolic substrates and cofactors whose intracellular availability becomes rate-limiting during ischemia, hypoxia, and oxidative stress: succinic acid feeds directly into mitochondrial Complex II (succinate dehydrogenase), bypassing the NAD-dependent steps of the Krebs cycle that fail under hypoxic conditions; inosine supports purine salvage and ATP resynthesis; nicotinamide replenishes the NAD+ pool consumed by poly(ADP-ribose) polymerase activation during ischemic injury; and riboflavin provides the FAD prosthetic group required for succinate dehydrogenase function and for multiple flavoprotein-dependent antioxidant enzymes including glutathione reductase.

The clinical evidence base for Cytoflavin spans ischemic stroke (acute and chronic cerebral ischemia), traumatic brain injury, diabetic polyneuropathy, postoperative cognitive decline in elderly surgical patients, post-COVID-19 asthenic syndrome, and organic asthenic disorder. The largest and most rigorous published trial is the CYLINDER study, a multicenter, double-blind, placebo-controlled, randomized trial in 216 patients with type 2 diabetes mellitus and symptomatic distal sensorimotor diabetic polyneuropathy conducted across 10 Russian clinical centers, which reported a statistically significant reduction in Total Symptom Score (TSS change of negative 2.65 points in the experimental group versus negative 1.73 points in the placebo group, p less than 0.001) after a sequential intravenous-then-oral treatment regimen. In acute ischemic stroke, multicenter studies have demonstrated marked reduction in neurological deficit severity by day 10 and higher probability of favorable functional outcome compared to standard-of-care controls. The CITADEL prospective randomized study demonstrated a pronounced anti-asthenic effect and correction of cognitive impairments in post-COVID-19 rehabilitation. An international, multicenter, randomized, single-blind, placebo-controlled trial (NCT04631484) evaluating Cytoflavin in moderate traumatic brain injury in adults was completed in 2024, with results published in Frontiers in Neurology in 2025, representing the first large-scale international trial of the compound outside the Russian Federation and Commonwealth of Independent States.

Cytoflavin is registered as a medicinal product in the Russian Federation and in Vietnam. The manufacturing facility holds GMP EU certification. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by other major Western regulatory authorities. The clinical literature is predominantly in Russian-language journals, with an expanding body of English-language publications in international peer-reviewed venues. The safety profile across published clinical studies is favorable; the principal adverse events are transient epigastric discomfort, headache, hyperuricemia (attributable to inosine-derived purine catabolism), and rare hypersensitivity reactions. No serious adverse events attributable to the drug have been reported in published controlled trials.

This monograph reviews the composition, identification, and formulation chemistry of Cytoflavin; the individual and composite pharmacology of its four active components; the pharmacokinetic considerations for each component; the preclinical pharmacology; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative neuroprotective metabolic agents (Mexidol, Actovegin, Cerebrolysin, citicoline, and Reamberin) against Cytoflavin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1583Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Hopantenic acid

Our opinion on this compoundEstablished workhorse

36/100

A Soviet-era pantoyl-GABA hybrid with genuinely interesting multi-pathway pharmacology undermined by thin Western evidence and a documented hepatotoxic liability

Hopantenic acid is one of those compounds where the development history tells you more than the pharmacology does. Synthesized in Japan in the 1950s, registered clinically in both Japan and the Soviet Union in the late 1970s, then withdrawn in Japan after a cluster of Reye-like encephalopathy cases through the 1980s. Thats a trajectory that should give any bench scientist pause before committing serious resources.

The mechanism story is interesting on paper. You’ve got a pantoyl-GABA conjugate that crosses the blood-brain barrier, interacts at GABA-B receptors, and produces secondary cholinergic facilitation through enhanced high-affinity choline transport into cortical and hippocampal synaptosomes. The work from Nakahiro et al. (1988) and a handful of Japanese follow-up groups established the choline acetyltransferase stimulation clearly enough to be credible. A multi-pathway molecule with a BBB-permeable design is genuinely worth a second look. In practice, though, the GABA-B activity clocks at approximately 0.2 percent relative to GABA itself in radioreceptor assays. That isn’t a mechanism you build a research program around.

The cholinergic facilitation angle is the more defensible claim. If you’re studying GABAergic modulation of cholinergic tone in a hippocampal slice preparation, hopantenic acid is a legitimate probe. It’s not, however, the cleanest probe available, because it comes with a metabolic liability baked into the same molecule: competitive antagonism at pantothenate kinase. The phosphorylated metabolite inhibits phosphopantothenoylcysteine synthetase and reduces cellular CoA. Noda et al. (1991) reproduced the Reye-like encephalopathy phenotype in dogs. This isn’t a theoretical concern. It’s a documented mechanistic liability that adds a confound to any chronic-dosing study and forces pantothenic acid co-supplementation, complicating experimental design in ways that matter.

Then there’s the evidence geography problem. Honestly, the entire clinical base for cognitive, ADHD, and cerebrovascular indications lives inside the Russian Federation’s PIQ-Pharma clinical network. The most rigorous trial on record is a 100-child, double-blind, placebo-controlled ADHD study that showed statistically significant improvement on the ADHD-DSM-IV scale at 30 mg/kg/day over four months. That’s a reasonable design for its context. It has not been replicated outside Russia. The broader literature for cerebrovascular cognitive impairment and perinatal encephalopathy is methodologically uneven in ways that make evidence synthesis genuinely difficult.

We think hopantenic acid deserves a read as a historical artifact of Soviet nootropic pharmacology and as a case study in how CoA pathway antagonism can emerge as an unintended liability in a hybrid molecule. As an active research priority for a bench scientist with options, it’s hard to justify. Better-characterized cholinergic facilitators exist, GABA-B pharmacology is better served by baclofen and its derivatives, and the safety overhang from the CoA antagonism demands careful justification before any in-vivo work begins. Interesting enough to know about, not compelling enough to prioritize.

Novelty

32

Mechanism promise

47

In-category differentiation

35

Evidence quality

30

Translational signal

38

Research bench value

28

Rationale Scores reflect a decades-old compound with registered clinical use confined to Russia, a literature dominated by unvalidated Russian-language publications, and a well-documented Reye-like encephalopathy mechanism that complicates any chronic-dosing research design; the composite GABAergic-cholinergic-CoA pharmacology is genuinely unusual but insufficient to overcome the evidence geography and safety picture.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pantoyl-GABA conjugate nootropic with GABAergic, cholinergic, and pantothenic acid-related central nervous system activity

A synthetic homolog of pantothenic acid in which beta-alanine is replaced by gamma-aminobutyric acid, developed in the Soviet Union and Japan as a nootropic and neuroprotective agent with registered indications across pediatric and adult neurology in the Russian Federation.

Abstract

Hopantenic acid (homopantothenic acid, D-homopantothenic acid, N-pantoyl-GABA) is a synthetic structural analog of pantothenic acid (vitamin B5) in which the beta-alanine moiety is replaced by gamma-aminobutyric acid (GABA), producing a hybrid molecule that combines GABAergic pharmacology with pantothenate-related metabolic activity and the capacity to cross the blood-brain barrier, a property that free GABA lacks. The compound was first synthesized in the 1950s in Japan, entered clinical use as the calcium salt (calcium hopantenate) in Japan in 1978 and in the Soviet Union in 1977, and is registered in the Russian Federation under the brand names Pantogam and Pantocalcin for a broad range of neurological, psychiatric, and developmental indications in children and adults, including cognitive impairment of cerebrovascular origin, attention deficit hyperactivity disorder, perinatal encephalopathy, cerebral palsy with hyperkinetic features, epilepsy adjunctive therapy, neurogenic bladder disorders, stuttering, and tic disorders. A racemic formulation (D,L-hopantenic acid, marketed as Pantogam Active) was introduced in Russia in 2008 and exhibits enhanced anxiolytic and anticonvulsant properties attributed to the L-isomer’s interaction with GABA-A receptors and dopamine D2 receptors. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by any Western regulatory authority. The molecular pharmacology of hopantenic acid is multifaceted. At the neurotransmitter level, the compound acts as a weak agonist at the GABA-B receptor complex, with a cross-reactive potency of approximately 0.2 percent relative to GABA in radioreceptor assays, and interacts with GABA-A receptors and dopamine D2 receptors at higher concentrations. In parallel, hopantenic acid enhances high-affinity choline transport into cortical and hippocampal synaptosomes and stimulates choline acetyltransferase activity, producing a secondary cholinergic facilitation that is the principal basis for the nootropic and antidementia pharmacology characterized in preclinical studies by Nakahiro et al. (1988) and others [1, 2]. At the metabolic level, the compound is a competitive antagonist of pantothenic acid at the pantothenate kinase step of coenzyme A (CoA) biosynthesis; phosphorylation by pantothenate kinase produces phospho-hopantenic acid, which potently inhibits phosphopantothenoylcysteine synthetase and reduces cellular CoA levels [3]. This pantothenic acid antagonism is the molecular basis for the most serious reported adverse effect of the compound: a Reye-like syndrome of acute encephalopathy with hepatic steatosis, hyperammonemia, and hypoglycemia reported in multiple case series in Japan during the 1980s, principally in elderly and pediatric patients on chronic high-dose therapy, and reproduced in dogs by Noda et al. (1991) [4, 5, 6]. The encephalopathy was preventable by concurrent pantothenic acid supplementation, confirming the antagonistic mechanism. Pharmacokinetics following oral administration of the calcium salt are characterized by rapid absorption (time to peak plasma concentration approximately 1.5 hours), moderate oral bioavailability (approximately 64 percent in preclinical models), an elimination half-life of approximately 6.7 hours, and predominantly renal excretion without significant hepatic metabolism [7]. The clinical evidence base for hopantenic acid is dominated by Russian-language publications of variable methodological rigor, with the most robust trial being a multicenter, double-blind, placebo-controlled study of Pantogam in 100 children with attention deficit hyperactivity disorder, which reported statistically significant improvement on the ADHD-DSM-IV rating scale and sustained attention measures over four months at 30 mg/kg/day [8]. Additional clinical evidence supports the use of the racemic formulation (Pantogam Active) for cognitive and anxiety disorders in patients with arterial hypertension and chronic cerebral ischemia [9, 10]. This monograph reviews the chemistry, synthesis, and stereochemistry of hopantenic acid; the multifaceted mechanism of action spanning GABAergic, cholinergic, and CoA-related pathways; the pharmacokinetic profile; the clinical evidence across registered and investigational indications; the Reye-like encephalopathy safety signal and its mechanistic basis; sourcing and quality verification; reconstitution and handling; stack interactions; and a structured comparative assessment of five alternative nootropic and GABAergic compounds against hopantenic acid on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1581Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026

←Previous Page

1 … 10 11 12 13 14 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.